Trulicity Monitoring Schedule: Labs & Exams You Need on Dulaglutide

Baseline Labs Before Starting Dulaglutide

Every patient should have a complete metabolic snapshot drawn before the first 0.75 mg injection. This is not optional. The ADA Standards of Care 2024 specify that glycemic, renal, and hepatic assessments precede any new antihyperglycemic agent.

The minimum baseline panel includes HbA1c, fasting glucose, comprehensive metabolic panel (which captures creatinine, eGFR, electrolytes, and hepatic transaminases), fasting lipid profile, and a spot urine albumin-to-creatinine ratio (UACR). Body weight and blood pressure should be documented as reference points for treatment response. In the REWIND trial (N=9,901), mean baseline HbA1c was 7.2%, highlighting that dulaglutide is often initiated in patients who are near glycemic goal but require cardiovascular risk reduction. Without a documented baseline, you cannot attribute later changes to the drug versus disease progression.

Thyroid-stimulating hormone (TSH) should be measured if clinical suspicion of thyroid disease exists, though the FDA prescribing information does not mandate routine calcitonin screening in humans. The boxed warning for medullary thyroid carcinoma (MTC) is based on rodent data at exposures 2 to 74 times the human dose. Routine serum calcitonin lacks sensitivity and specificity in the general diabetic population, per the ATA 2015 guidelines.

HbA1c Monitoring Intervals

Check HbA1c at 3 months after initiation, again at 6 months, and then every 6 months once stable. The 3-month mark aligns with the full erythrocyte lifespan needed to reflect a true steady-state glycemic average.

In AWARD-1 (N=978), dulaglutide 1.5 mg produced a mean HbA1c reduction of 1.51% at 26 weeks versus 0.46% for placebo [1]. The clinical implication: if HbA1c has not dropped by at least 0.5% at the first 3-month check, the clinician should verify adherence, injection technique, and whether dose escalation from 0.75 mg to 1.5 mg (or further to 3.0 mg or 4.5 mg) is warranted. The Endocrine Society Clinical Practice Guideline on pharmacological management of T2D recommends treatment intensification if HbA1c remains above target after 3 months on a maximally tolerated dose.

Patients already at HbA1c goal who start dulaglutide for cardiovascular benefit (as supported by REWIND, which showed a 12% reduction in 3-point MACE) still need glycemic surveillance. Hypoglycemia risk is low with GLP-1 receptor agonists alone, but combining dulaglutide with sulfonylureas or insulin demands more frequent self-monitored blood glucose and possibly continuous glucose monitoring review at each visit.

Renal Function Monitoring

Measure eGFR and UACR at baseline, 3 months post-initiation, and at minimum annually thereafter. Patients with eGFR <60 mL/min/1.73 m² need checks every 3 to 6 months.

The AWARD-7 trial (N=577) specifically enrolled patients with moderate-to-severe CKD (eGFR 15-60) and found dulaglutide 1.5 mg preserved eGFR better than insulin glargine over 52 weeks. The REWIND renal substudy demonstrated a 15% reduction in the composite renal outcome (new macroalbuminuria, sustained decline in eGFR ≥30%, or chronic renal replacement therapy) [2]. These findings suggest a nephroprotective signal, but they do not eliminate the need for monitoring.

GLP-1 receptor agonists can cause nausea and vomiting, particularly during dose titration. Dehydration from persistent GI symptoms may precipitate acute kidney injury in vulnerable patients. The FDA safety communication explicitly warns prescribers to monitor renal function in patients reporting severe GI adverse effects. If eGFR drops by more than 20% from baseline without an obvious reversible cause, consider holding the drug and investigating.

Dr. Katherine Tuttle, executive director for research at Providence Health Care, stated in her REWIND renal analysis: "The renal benefits were consistent across baseline eGFR categories, suggesting GLP-1 receptor agonists should be considered part of a comprehensive kidney protection strategy in type 2 diabetes."

Lipid Panel and Cardiovascular Markers

Draw a fasting lipid panel at baseline and again at 6 to 12 months. GLP-1 receptor agonists modestly reduce total cholesterol, LDL, and triglycerides.

In a pooled analysis of the AWARD program published in Diabetes, Obesity and Metabolism, dulaglutide 1.5 mg reduced fasting triglycerides by approximately 12% and total cholesterol by 2-4% compared to placebo at 26 weeks. These effects are secondary to weight loss and improved insulin sensitivity, not direct lipid-lowering action. They do not replace statin therapy in patients who meet criteria.

Blood pressure tends to decrease by 1-3 mmHg systolic on dulaglutide. Monitor at each clinic visit. The REWIND population had a median systolic BP of 137 mmHg at baseline, and the cardiovascular benefit was observed independently of BP changes [1]. Heart rate increases of 2-4 bpm have been documented across GLP-1RA trials. The EMA assessment report for dulaglutide noted this is a class effect, likely mediated by sinoatrial node GLP-1 receptors. Clinical significance remains unclear, but patients with resting tachycardia or arrhythmia history warrant periodic pulse checks and ECG if symptomatic.

Hepatic Function Surveillance

Check ALT, AST, and alkaline phosphatase at baseline and at 6 months. Repeat annually or sooner if symptoms suggest hepatotoxicity.

Dulaglutide is not hepatotoxic per available evidence. The monitoring rationale is twofold. First, many patients with T2D have concurrent non-alcoholic fatty liver disease (NAFLD/MASLD), and serial transaminases track disease trajectory. Second, a meta-analysis of GLP-1RA trials (N=25,199) published in the Journal of Hepatology found that GLP-1 receptor agonists reduced ALT by a mean of 3.8 IU/L and hepatic fat fraction on MRI, suggesting potential therapeutic benefit. Serial monitoring quantifies this benefit and can inform decisions about dedicated MASLD therapy.

If ALT rises above 3 times the upper limit of normal without alternative explanation, discontinue dulaglutide and investigate. This threshold aligns with FDA guidance on drug-induced liver injury assessment.

Pancreatic Safety Monitoring

No routine amylase or lipase screening is recommended. Educate patients about pancreatitis warning signs at every visit.

The FDA label reports acute pancreatitis in 0.1% of dulaglutide-treated patients versus 0.1% in comparator groups across the AWARD program. GLP-1 receptor agonists raise amylase and lipase by 10-20% from baseline as a pharmacologic effect without pathologic significance [3]. Routine measurement leads to false-positive alarms, unnecessary imaging, and inappropriate drug discontinuation.

The correct approach: instruct patients to report persistent severe abdominal pain radiating to the back, especially with vomiting. If pancreatitis is clinically suspected, obtain lipase (not amylase alone, which is less specific), imaging, and discontinue dulaglutide. Do not rechallenge after confirmed pancreatitis.

Patients with a history of pancreatitis represent a relative contraindication. The ADA does not absolutely prohibit GLP-1RA use in these patients but recommends heightened vigilance and documented informed consent.

Thyroid Monitoring: What the Evidence Actually Supports

Clinical thyroid examination at baseline and annually is sufficient for average-risk patients. Reserve calcitonin measurement for patients with MTC family history or MEN2 syndrome.

The FDA boxed warning stems from rodent carcinogenicity studies showing C-cell hyperplasia and thyroid C-cell tumors in rats exposed to dulaglutide. The mechanism involves sustained GLP-1 receptor activation on rodent C-cells, which express the GLP-1 receptor at high density. Human thyroid C-cells express GLP-1 receptors at markedly lower levels. A 10-year pharmacovigilance analysis of GLP-1RA post-marketing data found no signal for increased MTC incidence in humans above background rates.

The practical protocol: document thyroid palpation findings at baseline. Ask about neck mass, dysphagia, or hoarseness at follow-up visits. If a thyroid nodule is detected, evaluate per standard ATA guidelines (ultrasound, FNA if indicated) regardless of GLP-1RA use. Do not reflexively discontinue dulaglutide for an incidental thyroid nodule that proves benign on cytology.

Retinal Examination Before Rapid Glycemic Control

Obtain a dilated fundoscopic exam before starting dulaglutide in patients with existing diabetic retinopathy. Repeat at 6 months if HbA1c drops by more than 1.5% in the first 3 months.

The concern is not drug-specific. Rapid glycemic improvement from any intervention (insulin, GLP-1RA, bariatric surgery) can transiently worsen diabetic retinopathy, a phenomenon described since the DCCT in type 1 diabetes. The SUSTAIN-6 trial documented retinopathy complications with semaglutide (HR 1.76), primarily in patients with pre-existing retinopathy who experienced rapid HbA1c decline. REWIND did not show this signal with dulaglutide, likely because the glycemic improvement was more modest (mean HbA1c reduction 0.61% vs placebo) [1].

The ADA recommends that clinicians use clinical judgment: patients entering with HbA1c above 10% who are expected to improve rapidly on dulaglutide plus other agents should have retinal status documented before and 3-6 months after initiation.

Injection Site Assessment and Technique Review

Inspect injection sites at every in-person visit. Review rotation patterns every 6 months.

Dulaglutide is delivered via a single-dose prefilled pen to the abdomen, thigh, or upper arm. Injection site reactions occur in approximately 1-2% of patients per the AWARD pooled safety database. Lipohypertrophy from repeated injection into the same area impairs drug absorption and leads to erratic glycemic control. Unlike insulin, which is injected daily or multiple times daily, once-weekly dulaglutide poses lower risk for lipohypertrophy, but it still occurs in patients who always inject in the exact same spot.

The clinician should palpate common injection zones for subcutaneous nodules or textural changes. If lipohypertrophy is detected, instruct the patient to avoid that site for at least 8 weeks while rotating to unaffected areas. Confirm the patient is using the pen correctly: that the click is audible, the needle guard locks after injection, and the full 0.5 mL volume is delivered by holding the pen in place for 10 seconds post-activation.

Weight and Body Composition Tracking

Record weight at every visit. Consider body composition assessment (waist circumference or DEXA) at baseline and annually.

Dulaglutide produces dose-dependent weight loss. In AWARD-11 (N=1,842), the 4.5 mg dose achieved 4.6 kg mean weight loss at 36 weeks versus 2.3 kg with 0.75 mg [4]. Weight trajectory informs dose titration decisions: patients losing weight steadily may not need higher doses if glycemic targets are met. Patients gaining weight despite dulaglutide adherence require reassessment of concurrent medications (sulfonylureas, thiazolidinediones, insulin) and dietary intake.

The REWIND trial enrolled patients with mean BMI of 32.3 kg/m². The cardiovascular benefit was observed across BMI subgroups. Weight loss alone does not explain the MACE reduction. Monitoring weight helps track one dimension of response but should not be the sole measure of treatment success.

Putting the Schedule Together: A Practical Timeline

Here is the consolidated monitoring calendar based on ADA Standards of Care, FDA labeling, and evidence from the AWARD and REWIND programs:

Before first injection: HbA1c, CMP (includes creatinine/eGFR, electrolytes, LFTs), fasting lipids, UACR, weight, BP, thyroid palpation, retinal exam if retinopathy present, pregnancy test if applicable.

Month 3: HbA1c, basic metabolic panel (creatinine/eGFR focus), assess GI tolerance, review injection technique, weight.

Month 6: HbA1c, CMP, fasting lipids, UACR, weight, injection site exam.

Month 12 and annually: HbA1c, CMP, fasting lipids, UACR, weight, thyroid palpation, injection site exam, retinal exam per ADA schedule.

At every visit: BP, weight, symptom review (GI tolerance, abdominal pain, neck symptoms), adherence assessment, hypoglycemia review if on concomitant sulfonylurea or insulin.

Patients with CKD stage 3 or higher should have eGFR checked every 3 months for the first year, then every 3-6 months based on trajectory [5].